Monafox (Moxifloxacin Hydrochloride)

Moxifloxacin hydrochloride blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition stops bacterial cell division, leading to a bactericidal effect against a broad range of Gram‑positive and Gram‑negative eye pathogens.

The dosing regimen for Monafox is determined by the prescribing clinician based on the specific infection, severity, and patient factors. The prescriber will provide detailed instructions on the number of drops, frequency, and duration of therapy.

Safety data for Monafox in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Monafox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monafox (moxifloxacin) is a fourth‑generation fluoroquinolone offering broad‑spectrum coverage, including many resistant strains, and has good ocular penetration. Compared with older agents such as ciprofloxacin or ofloxacin, it often requires less frequent dosing and may be effective against a wider range of pathogens.

Monafox should be stored at ambient temperature, protected from light and moisture, and kept in its original container. Do not freeze the product. If the solution becomes cloudy or discolored, discard it and obtain a new supply.

Monafox is applied as eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops into the conjunctival sac. Close the eye gently for a few seconds and avoid blinking excessively.

Serious adverse events, though rare, include corneal ulceration or perforation, severe allergic reactions such as anaphylaxis, and vision loss. Patients should seek immediate medical attention if they experience worsening pain, redness, or any signs of a severe reaction.

Monafox should not be used by individuals with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any excipients in the formulation. Caution is also advised for patients with a history of tendon disorders, uncontrolled epilepsy, or those taking interacting systemic medications.